| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5227534d5452763715e3b63f856057cf |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06F19-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16C20-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06F19-24 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B40-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G06F19-00 |
| filingDate |
2013-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c5bf1522c10ef2990b77d45e2243fa9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd26548e9e3af118c70541f7e55709e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c79b8aa79a46cd98c36268233860b58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b6397be8955f2b97539f65c90f46283
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0168a2a30f0f6003cb9cd56d610a2d87
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9d21b7b1d08fd559b81c8eacfa54a85 |
| publicationDate |
2015-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2015347679-A1 |
| titleOfInvention |
Predictive outcome assessment for chemotherapy with neoadjuvant bevacizumab |
| abstract |
In a predictive outcome assessment test for predicting whether a patient undergoing a breast cancer treatment regimen will achieve pathological complete response (pCR), differential gene expression level information are generated for an input set of genes belonging to the TGF-β signaling pathway. The differential gene expression level information compares baseline gene expression level information from a baseline sample ( 70 ) of a breast tumor of a patient acquired before initiating ( 71 ) a breast cancer therapy regimen to the patient and response gene expression level information from a response sample ( 72 ) of the breast tumor acquired after initiating the breast cancer therapy regimen by administering a first dose of bevacizumab to the patient. A pCR prediction for the patient is computed based on the differential gene expression level information for the input set of genes belonging to the TGF-β signaling pathway. Related predictive outcome assessment test development methods are also disclosed. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10902591-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019251688-A1 |
| priorityDate |
2012-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |